Lion Bioscience to Acquire Trega for $35 Million | GenomeWeb

NEW YORK, Dec 27 - Lion Bioscience will acquire Trega Biosciences in a deal valued at $35 million, the companies announced Wednesday.

Under the terms of the agreement, Lion will issue new shares out of its authorized capital to acquire all outstanding shares of Trega in a stock-for-stock transaction using Lion's American Depositary Shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.